Instituto Grifols, S.A.
31
2
2
25
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 30/100
12.9%
4 terminated/withdrawn out of 31 trials
86.2%
-0.3% vs industry average
48%
15 trials in Phase 3/4
72%
18 of 25 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (31)
Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
Role: collaborator
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
Role: lead
Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%
Role: collaborator
Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome
Role: lead
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
Role: collaborator
Albumin Replacement Therapy in Septic Shock
Role: collaborator
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Role: collaborator
FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis
Role: lead
A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants
Role: lead
HEAL STUDY (Hepatic Encephalopathy and Albumin Study)
Role: collaborator
Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia
Role: collaborator
Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19
Role: lead
Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)
Role: lead
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
Role: lead
Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis
Role: lead
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
Role: lead
Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.
Role: lead
Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"
Role: lead
Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery
Role: lead
IGIV Study for Chronic ITP Patients Ages 3-70
Role: collaborator